Pherecydes Pharma Announces Its 2022 Annual Financial Results and Specifies Its Development Plan For 2023
Proposed strategic combination with Erytech Pharma intending to create a global leader in phage therapies: Acceleration in the development of phage therapy in antimicrobial resistance
United States France General Ile De France Dusan Oresansky Nicolas Fossiez Pherecydes Pharma Didier Hoch
Source: finanznachrichten.de